News & Updates

More infections diagnosed after COVID-19

Patients with an acute SARS-CoV-2 infection tend to have a subsequent increase in diagnosed infections over the next 12 months, according to new research.

Original New Drug Application Approvals by US FDA (16-31 March 2025)

New drug applications approved by US FDA as of 16-31 March 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Vaccination crucial to integrated dengue prevention and control in SEA

Southeast Asia (SEA) is one of the hotspots for dengue infections, with Indonesia and Thailand among the highly endemic countries. At a Takeda-sponsored symposium held during the 2nd APIC-ADVA Asia Pacific Summit on Infectious Diseases and Immunization in Singapore, experts focused on vaccination as an integral component of a holistic dengue prevention and control strategy in SEA.

*The editorial below is supported by Takeda Pharmaceuticals International AG Singapore Branch and is intended solely for informational purposes. Takeda has not influenced or contributed to the editorial content. While Takeda has provided financial support for the editorial, Takeda shall not be held responsible or liable for any errors, omissions, or inaccuracies in such information.

HIV-exposed, uninfected children show growth lag

Children exposed to HIV but uninfected appear to have an initial growth deficit at birth that persists for at least the first 24 months of life, according to a meta-analysis.

World’s first liquid-bodied robot eradicates biofilms on complex surfaces

An international research team led by the Chinese University of Hong Kong (CUHK) has developed the world’s first liquid-bodied robot for biofilm eradication on complex surface topographies.

Ganciclovir/valganciclovir tied to adverse effects in preterm infants with CMV

Preterm and very low birthweight (VLBW) infants who have been treated with ganciclovir (GCV) or oral valganciclovir (valGCV) for cytomegalovirus (CMV) disease are more likely to experience adverse events than term infants, a study has shown.

Penicillin allergy delabelled in 90 percent of patients after evaluation

Research from Queen Mary Hospital in Hong Kong shows that 90 percent of patients with suspected penicillin allergy were delabelled after undergoing Prospective Assessment of Penicillin Allergy (PAPA), and one in six of them received penicillins safely ≥6 months later.

Zero HIV acquisition, high persistence through 1 year with cabotegravir LA as PrEP for MSM, transgender men

“Zero HIV acquisition” is a milestone that cabotegravir LA as PrEP has realized in the PILLAR real-world trial, along with high persistence observed through 12 months among 201 MSM and transgender men

Cetuximab linked to pocket infections after central venous port placement

Cetuximab therapy appears to induce skin complications in patients following central venous port placement, reports a study.